Commentary Open Access
Volume 1 | Issue 2 | DOI: https://doi.org/10.33696/mentalhealth.1.006
The Loneliness, Loss and Reflections Set off by COVID-19
Susan E. Schwartz1,*
- 1International Association of Analytical Psychology
Susan E. Schwartz, firstname.lastname@example.org
Received Date: October 10, 2021
Accepted Date: November 02, 2021
Schwartz S. The Loneliness, Loss and Reflections Set off by COVID-19. J Ment Health Disord. 2021;1(2):36-40.
Copyright: © 2021 Schwartz S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
COVID-19 Clinical Research
While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.
Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View
Ketamine has long been used in the field of anesthesia . Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage
The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.
Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic?
Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.
Safety of Using Rituximab Therapy During COVID-19 Pandemic
Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia